A new paradigm in the treatment of the cardiovascular disease continuum: Focus on prevention

Hippokratia

Volumn 15, Issue 1, 2011, Pages 7-11

  Chrysant, S G ^a  

^a Oklahoma Cardiovascular and Hypertension Center   (United States)

Author keywords

Cardiovascular disease continuum; Diabetes mellitus; Dyslipidemia; Hypertension; Obesity; Review; Smoking

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; RENIN INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE CONTINUUM; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DEATH; DIASTOLIC DYSFUNCTION; DIET THERAPY; DRUG EFFICACY; DYSLIPIDEMIA; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SYSTOLIC DYSFUNCTION;

EID: 79251484689     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated. Clinical evidence of improved patient outcomes: Part 1: pathophysiology and clinical trial evidence. Circulation. 2006; 114: 2850-2870.
2. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, Hong Y, et al. Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association and the American Heart Association. Circulation. 2004; 109: 3244-3255.
3. Magnusen CG, Venn A, Thomson R, Juonala M, Srinivasan SR, Viikari JS, et al. The association of pediatric low and high density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood. J Am Coll Cardiol. 2009; 53: 860-869.
4. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation. 2007; 115: 459-467.
5. Grundy SM, Cleeman JI, Mertz CN, Brewer HB Jr, Clark LT. Implications of recent clinical trials for the National Cholesterol Education Program. Adult Treatment Panel III Guidelines. Circulation. 2004; 110: 227-239.
6. Tikkanen MJ, Szarek M, Fayyard R, Holme I, Cater NB, Faergeman O, et al. Total cardiovascular disease burden: Comparing intensive with moderate statin therapy: insights from the IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009; 54: 2353-2357.
7. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease, Treating to New Targets (TNT) Investigators. N Engl J Med. 2005; 352: 1425-1435.
8. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics -2007 update. A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2007; 115: e69-e171.
9. Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high- density lipoprotein cholesterol levels, triglycerides and the total cholesterol/high density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009; 55: 35-41.
10. Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci. 2006; 1084: 1-29.
11. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: A Japanese trial in IGT males. Diabetes Res Clin Pract. 2005; 67: 152-162.
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomized trial. Lancet. 2002; 359: 2072-2077.
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-234.
14. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care. 2007; 30: 162-172.
15. Poirier P, Giles TD, Bray GA, Hong Y, Stera JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss. An update of 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity and metabolism. Circulation. 2006; 113: 898-918.
16. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002; 288: 1723-1727.
17. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999; 100: 1481-1492.
18. Suk SH, Sacco RL, Boden-Abala B, Cheun JF, Pitman JG, Elking MS, et al. Abdominal density and risk for ischemic stroke. The Northern Manhattan Stroke Study. Stroke. 2003; 34: 1586-1592.
19. Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, Fortmann SP, et al. Population based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement for the American Heart Association Council on Epidemiology and Prevention. Interdisciplinary Committee for Prevention. Circulation. 2008; 118: 428-464.
20. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: The EVA syndrome. J Hypertens. 2008; 26: 1049-1057.
21. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004; 328: 1519-1528.
22. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976; 38: 46-51.
23. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: a meta- analysis of cohort studies. Arch Intern Med. 2000; 160: 939-944.
24. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003; 290: 86-97.
25. Gerber Y, Rosen LJ, Goldbourt U, Benyamini Y, Drory Y. Smoking status and long-term survival after first acute myocardial infarction. J Am Coll Cardiol. 2009; 54: 2382-2387.
26. Ambrose JA, Barua R S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004; 43: 1731-1737.
27. Fiore MC, Jaen CR, Baker TB. Treating tobacco use and dependence: 2008 update. Clinical practice guideline Rockville, MD: US Department of Health and Human Services. Public Health Service. 2008.
28. Perez GH, Nicolau JC, Romano BW, Laranjeira R. Depression: a predictor of smoking relapse in a 6 month follow-up after hospitalization for acute coronary syndrome. Eur J Cardiovasc Prev Rehabil. 2008; 15: 89-94.
29. Van Berkel TF, Boersma H, Roos-Hesselink JW, Erdman RA, Simoons ML. Impact of smoking cessation and smoking interventions in patients with coronary heart disease. Eur Heart J. 1999; 20: 1773-1782.
30. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Trial of preventing hypertension (TROPHY) investigators. Feasibility of treating pre-hypertension with an angiotensin receptor blocker. N Engl J Med. 2006; 354: 1685-1697.
31. LÓders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M, et al. The PHARAO study: prevention of hypertension with the angiotensin converting enzyme inhibitor ramipril in patients with high normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008; 26: 1487-1496.
32. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens. 2009; 23: 363-384.
33. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age- specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data from one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913.
34. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003- 2004 secondary prevention trials. Hypertens Res. 2005; 28: 385-407.
35. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008; 26: 1477-1486.
36. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996; 27: 1214-1218.
37. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003; 138: 10-16.
38. Dahlof B, Devereaux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. For the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension. (LIFE): a randomized trial against atenolol. Lancet. 2002; 359: 995-1003.
39. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens. 2002; 20: 2293-2300.
40. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular hypertrophy. Circulation. 2009; 119: 530-537.